Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced that five abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE